Pfizer Animal Health's Equine Herpes Virus (EHV) vaccine (Duvaxyn EHV 1,4) has been rebranded Equip EHV 1,4).
Pfizer says that EHV is carried by most horses in the UK1 and can cause respiratory disease, abortion and more rarely neurological disease. However, it is the more common sub-clinical infections that pose the most apparent issue for the competition client, with the associated loss of performance and the potential effect on the health of the whole yard.
Once infected with EHV, a horse can harbour the virus throughout its life and potentially shed the disease to other animals without showing any outward signs. According to the company, vaccinating helps to minimise the severity of the disease itself and importantly, can also help to reduce the amount of infective virus that is shed to other in-contact horses.
Equip EHV 1,4 is given as a primary course of two vaccinations, 4-6 weeks apart followed by a single dose every six months. It can also be used as an aid in the control of EHV-1 abortion - pregnant mares should be vaccinated with a single dose during each of the 5th, 7th and 9th months of pregnancy.
For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients contact your Pfizer Account Manager or Pfizer Animal Health, Walton Oaks, Tadworth, Surrey KT20 7NS.
Reference
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142.
Ceva Animal Health has produced a leaflet to help horse owners understand the cause, diagnosis and management of equine back pain.
The company says the management of back pain in the horse can be a particular challenge to vets and a source of frustration for owners. Early diagnosis is likely to be associated with a more favourable outcome but it's important to ensure that other causes of pain and poor performance such as lameness, are not contributing to the horse's clinical signs.
'Understanding back pain' explains the anatomy of the back, as well as the clinical signs of back pain, and how it is diagnosed, including the treatment options and the general prognosis. Copies of the new leaflet are available, free of charge, from your Ceva sales representative. Leaflets on 'Understanding bone spavin', 'Understanding navicular disease', 'Understanding sacroiliac disease' and 'Equidronate discharge instructions', are also available.
For further information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
A team of top equine vets is aiming to raise £125,000 for the Society for the Protection of Animals Abroad (SPANA) by travelling 3000 miles through Europe by motorbike between 22nd August and 9th September.
Sponsored by Elanco Animal Health, the seven-strong team is planning to travel through Belgium, the Netherlands, Germany, Switzerland, France, Italy, Morocco and Spain and deliver lectures to eight European and African veterinary schools in just two weeks.
Led by Professor Derek Knottenbelt from the University of Liverpool, the team also includes Professor Josh Slater from Royal Veterinary College, Dr John Burford from the University of Nottingham, Dr Caroline Hahn from the University of Edinburgh, Dr Michael Hewetson from the University of Helsinki, Ms Joanne Suthers from the University of Liverpool and Dr Edmund Hainisch from the University of Vienna. They are being supported by Jeremy Hulme, chief executive of SPANA, Nic Van Gelder, fundraising and supporter care administrator at SPANA and Cerian Stephens.
All money raised will provide SPANA with diagnostic and surgical equipment for the charity's veterinary clinics for working animals in Mali and Mauritania and for the further development of the Bamako Disabled Riding Centre in Mali.
Mike Brown, Elanco's UK and Ireland country director said: "We are delighted to be sponsoring the Vets with Horsepower European Tour which will raise vital funds for working animals in some of the world's poorest countries. This is just one of the many worthwhile initiatives we are supporting in 2012 which focus on alleviating world hunger, spearheading agricultural leadership, enhancing the human-animal bond and caring for the environment."
For further information on the Vets with Horsepower European Tour visit www.spana.org/horsepower.
ProteqFlu, the live attenuated canarypox equine influenza (EI) vaccine, has had its shelf life extended from 27 to 36 months.
Merial says the increased shelf life is the result of ongoing investment in vaccine research & development, and that the new data underpins the stability of modified live vaccine technology.
Merial highlights that ProteqFlu is the only equine flu vaccine in Europe to include the updated American clade 1 Ohio/03 strain in accordance with the OIE recommendations (2004).
The Federation of European Equine Veterinary Associations (FEEVA) and the European Federation of Farriers Associations (EFFA) have announced that they have joined forces to promote best practice in farriery.
The initiative is the result of recognition by both organisations that equine welfare is best served with the use of only properly trained farriers, working closely with veterinary surgeons as and when needed.
The organisations say that the main aims of the new partnership include:
The President of FEEVA, Professor Josh Slater said: "We look forward to working together at European level and encouraging member associations to do the same at national level, with the primary intention of enhancing equine health through first class farriery."
New research published in the Equine Veterinary Journal (EVJ) has shown that the use of standing sedation to repair lower limb fractures in racehorses produces similar results to surgery performed under a general anaesthetic, but with the advantages of less surgical complexity, time, cost and risk.
The study Short and long term results following standing fracture repair in 34 horses was conducted by Richard Payne and Polly Compston at Rossdales Equine Hospital1.
Standing fracture repair in the horse is a relatively new surgical procedure with very little follow-up data available. Treatable fractures sustained by racehorses in the UK have traditionally been repaired under general anaesthesia but it is well known that this carries an increased risk of anaesthetic-related death compared with other elective surgical procedures. However, despite the substantial increase in the number and type of surgical procedures performed under standing sedation over the past decade there has previously been very little work undertaken on standing fracture repairs.
The study looked at the case records of 34 Thoroughbred and Arab racehorses that had a lower limb fracture surgically repaired by one surgeon at Rossdales up until June 2011. The injuries included non-displaced fractures of the proximal phalanx, the third metacarpal bone and the third metatarsal bone, all of which are relatively common fracture sites in racehorses. Hospital records, owner and trainer telephone questionnaires and website research were used to evaluate follow-up. The short and long-term results were similar to those of horses undergoing repair of comparable fracture configurations under general anaesthesia, with 20 of the horses returning to racing within an average of 226 days.
This early research indicates potential for tangible benefits, including avoidance of the inherent risks of general anaesthesia as well as a reduction in surgical complexity and associated costs, leading the way for future research into larger cohorts of horses.
EVJ's Editor Celia Marr said: "The recent fatalities at the Grand National highlight that it is critical that the equine veterinary research community strives to reduce the prevalence of fractures in our racehorses. We also need to continue to seek better ways of treating those horses that do develop fractures and, while not every fracture will be amenable to this approach, this study is an important first step towards treating some of the non-displaced fractures that occur in racehorses without the need for anaesthesia."
1Short and long term results following standing fracture repair in 34 horses Richard Payne and Polly Compston, Equine Veterinary Journal ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00569.x
Pfizer Animal Health, maker of the equine wormers Equest and Equest Pramox, has unveiled www.wormingyourhorse.info, a new website which aims to make it easier for horse owners to understand and follow the most up-to-date principles of sustainable worm control.
Based on the company's Manage, Test, Plan, Dose campaign, Pfizer says the new website is designed to take the confusion out of equine worm control with clear, logical and easy-to-understand guidance and advice.
The four main sections use diagrams and text to explain how and why it's important to manage the worm challenge on the pasture; the role of faecal worm egg counts (FWECs); how history and management play a part in planning the best worm control programme and how to choose and use the right wormer at the right time of year.
There's an interactive and educational parasite page that shows the parasites that can affect the health of your horse. There are click through buttons on parts of the horse's anatomy revealing details about the appearance of each particular parasite, their lifecycle and the symptoms they can cause. In addition there's a section on frequently asked questions which provides no-nonsense answers to some of the most commonly asked questions about worm control.
Paul Blanc, Pfizer's equine brand manager said: "In developing our new website we have listened carefully to what horse owners really want and need to know. The result is a source of plain-speaking, unbiased facts and advice, providing horse owners with the most current thinking on sustainable worm control in a format they can really identify with."
Pfizer Animal Health is offering the chance to win £500 worth of CPD vouchers to UK veterinary surgeons who participate in the company's 5 minute online survey about Equine Herpes Virus (EHV).
Pfizer says the intention of the survey is to find out more about veterinary perceptions and understanding of this endemic disease and its effects on the UK's valuable equine industry. There are five multi-choice questions and the survey is available online from now until 31st May 2012. Vets who show their prowess in the skills-based section of the survey will be entered to win £500 of British Equine Veterinary Association CPD vouchers.
The survey is part of Pfizer's EHV awareness campaign to help vets encourage horse owners, yard managers, trainers and breeders to keep their horses protected from the effects of this common but often under-prioritised disease. The campaign includes the provision of information leaflets and the coordination of talks to help people, who manage horses, understand the severity of EHV and the best ways to prevent it.
According to Pfizer, the prevalence of EHV can be as high as 87.5% in the UK and latent infections in horses are frequently re-activated.1,2 The consequences can be serious, with abortion outbreaks proving to be a significant economic burden to owners, trainers and breeders.3,4 However, subclinical infections, although usually regarded as less serious, can remain unrecognised and can cause suboptimal performance in horses.
Sporadic, mild respiratory disease caused by EHV can lead to interrupted training and movement restrictions.4 Even after clinical recovery from EHV-1 or upper respiratory tract infections caused by EHV-4, some horse may develop 'poor performance syndrome'.5 These can all have serious financial repercussions on the equine industry.
To take part in the survey, visit http://www.ehvaware.com/. For further information on Pfizer's EHV campaign, to obtain literature for your practice or to book a talk for your clients please contact your Pfizer Account Manager.
1. Eddington et al. Equine Vet. J. 1994; 26 (2): 140-142. 2. Allen GP. 2002. Respiratory Infections by Equine Herpesvirus Types 1 and 4. In: P. Lekeux ed. 2002. Equine Respiratory Diseases. New York: International Veterinary Information Service. 3. Garré B et al. Vet Microbiol. 2007; 122(1-2): 43-51. 4. Lunn DP et al. J Vet Intern Med. 2009; 23(3): 450-61. 5. Slater, J. 2007. Equine Herpesvirus. In: Sellon, D. and Long, M. Equine Infectious Diseases. St Louis: Saunders. 144.
The London Fire Brigade has donated a life-size horse model to the Royal Veterinary College, to be used for student training.
The donation is in recognition of 11 years large animal handling training that the RVC has given firefighters from the London Fire Brigade.
The model horse has been named "Fireman Sam" by the students. Fireman Sam was officially presented to Vivienne Heys, the member of staff who organised and participated in the training throughout the entire 11 years, and to student trainers Vikki Wyse and Emma Howson, by London Fire Brigade Group Manager Andy Cane, Station Manager Mark Spier and Watch Manager Jim Wennell .
Andy Cane said how valuable the training has been for the London firefighters and how much the crews have enjoyed their visits to the Royal Veterinary College.
Vivienne emphasised that this programme would not have been possible without the students who have given their time on Wednesday afternoons to help firefighters learn the skills required when working with horses and cattle, and she also praised the staff who have volunteered their time and skills to keep this programme running for 11 years.
Endell Veterinary Group Equine Hospital in Wiltshire has stationed an equine veterinary surgeon on the Isle of Wight permanently to ensure that the island's numerous horses can receive rapid treatment when they need it.
Florus Oskam MRCVS is providing a routine and emergency mobile ambulatory service around the island 24 hours a day. Florus also has the back up of mainland ambulatory vets who also spend time on the Island. Appointments with specific vets to visit the island can also be arranged.
Florus said: "We have been providing a veterinary service on the Isle of Wight for the past 30 years and have a very loyal client base. For years they have been asking us for a permanent service on the island and we are delighted to be able to provide it at last."
Anita Niccolls, dressage rider and trainer on the Isle of Wight, added: "It's very reassuring to know that a vet of Florus's calibre is now resident on the Island and that we are able to have continuity of vet care should a horse need further treatment at the practice's equine hospital in Salisbury."
Kruuse has announced that it has become the exclusive distributor for VideoMed GmbH and its range of veterinary endoscopes and documentation systems.
VideoMed produces a range of equine and small animal endoscopes, gastroscopes and laryngoscopes that multifunction with a flexible documentation console. This provides a mobile capability to file, frame and forward digital and dicom images for review and referral diagnosis.
According to Kruuse, VideoMed products are synonymous with the very highest quality of design, function and reliability that have been developed through years of close working relationship with veterinary professionals. An after care and repair service is also provided by the company for its own and a range of other scopes.
Kruuse says the Overground scope gives a mobile, high resolution, recordable image that clearly determines functional and morphological abnormalities of the larynx, pharynx and upper respiratory system (see image right).
Andrew Groom, Managing Director, Kruuse UK Ltd., said: "This exciting agreement will further enhance our equine and small animal presence within the veterinary industry to bring even more leading edge technology to our customers."
For more information, visit www.kruuse.com and http://www.videomed-gmbh.de/
Picture courtesy of:Neil Townsend MSc BVSc Cert ES (Soft Tissue) DipECVS MRCVSClinician in Equine Soft Tissue SurgeryPhilip Leverhulme Equine Hospital
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
Researchers at the University of Saskatchewan's Western College of Veterinary Medicine (WCVM) are carrying out a survey of equine practitioners to discover, amongst other things, just how common Cushing's disease is internationally.
The 16-question survey was launched this month and will be available for a further six months at www.wcvm.com/veterinarians/cushings_survey.php
Dr. James Carmalt, an equine surgeon and associate professor in the WCVM's Department of Large Animal Clinical Sciences said: "Our objective is to determine the true prevalence of Cushing's disease worldwide, because until now, previous surveys were only based in the U.S."
Dr. Carmalt is also a PhD student in equine neurophysiology through the western Canadian veterinary college's Department of Veterinary Pathology. He and his graduate supervisor, veterinary pathologist Dr. Andrew Allen, are beginning to explore a new treatment methodology for equine Cushing's disease.
Researchers will use practitioners' responses to the brief survey to determine the incidence of the disease and the most common treatment protocols being used by practitioners in countries around the world. They also want to evaluate the need for developing new treatment methodologies. Dr Carmalt said: "Right now, the only available treatment for Cushing's disease requires daily dosing of medications for the rest of the horse's life. It's onerous, time consuming and a huge management challenge.
"If the responses from this survey reflect our impression that practitioners need a new option to offer their clients, our ultimate goal is to develop a one-time treatment for the disease so daily medications for Cushing's disease become unnecessary."
For more information about the Cushing's disease survey for equine practitioners, please contact Dr. James Carmalt (james.carmalt@usask.ca). As part of the survey, practitioners can also provide their email addresses if they wish to receive a copy of the survey results.
Protek Biochem Ltd., a company set up by champion horse-rider Debbie Topping, has won the rights to sell Envirocair Veterinary, a new range of disinfectants and sanitisers targeted at dogs, cats and other domestic pets, as well as horses and farm animals.
The product is claimed to kill 99.99% of all viral, bacterial and fungal infections, and lasts for 14 days.
Debbie said: "I did not consider myself a businesswoman, just a normal horse-rider and animal lover. However, I was so impressed when I tried Envirocair Veterinary that, when I was offered the opportunity to become the main UK distributor, I jumped at the chance."
According to the company, the product is being used by a number of the horses and trainers heading to the London Olympics in 2012. It is now being rolled out across the rest of the UK's animal care sector.
Debbie says that veterinary surgeons, farmers, dog kennels, animal rescue centres, breeders and others will all be able to benefit from the new product: "Envirocair Veterinary doesn't harm skin or irritate the respiratory tract, so you don't need to get dressed up in special clothing every time you use it.
"Used properly, it quite literally kills the threat of major animal diseases such as parvovirus in dogs, which can otherwise be fatal in less than 72 hours.
"It's not an exaggeration to say that Envirocair will protect the health and even save the lives of countless numbers of animals across the UK."
Debbie signed the distribution agreement with the manufacturer Biotech International Ltd last month, before officially launching Envirocair Veterinary this week.
For more information on Protek Biochem Ltd or Envirocair Veterinary, visit http://www.protekbiochem.com/.
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
Veterinary practices are being urged to raise awareness of summer skin conditions, such as sweet itch, following research carried out by Elanco Companion Animal Health, distributor of Cavalesse, which revealed that vets only tend to be consulted after horse owners have tried to manage the condition themselves (73%), or if the clinical signs have become severe (67%), potentially leading to major welfare implications.
According to the research, this is despite the fact that over half (55%) of owners of a horse with sweet itch showed concern that their horse will suffer, and nearly half being stressed about the way the condition will affect it (47%). While many horse owners are fairly knowledgeable about the causes of sweet itch and its clinical signs, over a quarter of respondents (26%) did not start managing the condition before the midge season in the spring, which may make managing the condition more frustrating. Nearly a third (31%) stated that they had to curtail their activities with their horse due to welfare, aesthetic and behavioural issues, such as head shaking, rubbing, unpredictability and aggression.
Ed Whittle, technical consultant at Elanco Companion Animal Health said: "86% of those questioned considered sweet itch to be a very serious welfare issue if left untreated, with the worst aspects of the condition being the suffering and distress caused by the constant irritation which affects the quality of life of the horse. Over half (55%) felt that sweet itch had adversely affected the behaviour of their horse, making them difficult to handle or ride. Veterinary practices should be proactively talking to their clients about summer skin conditions such as sweet itch to help alleviate the suffering and distress caused by this frustrating disease."
Elanco says it will be joining forces with the British Horse Society (BHS), The Blue Cross, The Horse Trust, Redwings Horse Sanctuary and World Horse Welfare (WHW) to raise awareness of summer skin conditions, such as sweet itch, during Sweet Itch Awareness Month (SIAM) in March. The campaign will highlight the preventative measures that should be carried out to help alleviate sweet itch and the importance of management of the condition before the start of the midge season in the spring.
Lee Hackett, head of welfare at the BHS, said: "The results of this survey show just how important raising awareness of sweet itch is. All of us, whether we are welfare organisations or vets, need to play our part in educating owners about sweet itch in the hope that they will seek expert advice at an earlier stage and reduce the number of horses that suffer as a result of this condition."
Kerry Taylor, education officer at The Blue Cross, said: "The Blue Cross is pleased to be supporting the sweet itch campaign to raise awareness of the physical and mental impact this condition has on horses. During our May 2011 National Equine Health Survey, skin problems came out the top syndrome affecting horses, and we continue to see many horses coming into our care suffering from sweet itch. Prevention and early treatment is key to managing the potentially debilitating condition."
For further information on sweet itch, Sweet Itch Awareness Month or Cavalesse, please visit http://www.fidavet.com/, or contact Elanco Companion Animal Health, Lilly House, Priestley Road, Basingstoke, RG24 9NL, 01256 353131.
Sweet itch - effect on horse and owner. Mo Gannon & Associates. Web survey in November 2011. 351 responses - owners who have owned horses with sweet itch in the last two years.
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
The University of Bristol's Langford Veterinary Services (LVS) has announced the completion of its new clinical facilities.
The first phase of the £13 million development includes a new small animal surgery building, comprising five theatres, an ICU, a dedicated anaesthesia induction and recovery and an imaging suite.
The imaging suite comprises a 16-slice CT scanner, for small animals and horses, conventional digital radiography with a DR system, a high-resolution fluoroscopy, diagnostic ultrasound, echocardiography, scintigraphy and a high resolution 1.5 tesla MRI scanner available seven days a week.
Lynne Hill, Chief Executive of LVS, said: "The new facility provides state-of-the art diagnostic imaging facilities at all times, to help the animals under our care."
LVS highlights the case of Gainsborough, an eight-year-old Irish draught gelding, to illustrate the benefits of its new facilities. The horse, used for jumping and endurance, was initially presented to the Equine Hospital in October 2010, with clinical signs including nasal airflow obstruction and discharge, which was limiting his athletic capabilities.
Using videoendoscopy and radiography, a space-occupying mass was diagnosed in the paranasal sinuses impinging into the nasal cavity. With the horse conscious, but sedated, using regional local anaesthetic nerve blocks, the bulk of the mass was removed and he returned to work. However, the owner reported a recurrence of the clinical signs and he was returned to the clinic for reassessment.
The new imaging suite, only one of a few such units in the UK, has been adapted to enable the imaging of a horse's head while conscious using a frictionless air plinth. The adaptation allows detailed imaging of both bone and soft tissue structures within a horse's head, without requiring a general anaesthetic.
Using the new imaging suite, Gainsborough's CT examination revealed a portion of the mass, which had been inaccessible to the previous keyhole surgery, had expanded into the nasal cavity. The detail of the images enabled careful planning of a second operation that facilitated removal of the large remnant of the mass, which appeared to be benign, with minimal collateral trauma.
In addition to imaging the heads of conscious horses, dogs and cats are able to undergo complete body scans using the same unit while anaesthetised. As well as enabling detection and diagnosis of lesions without invasive or painful tests at an earlier stage, the unit will facilitate operative planning and add to the body of knowledge of disease pathogenesis.
For more information about LVS, visit: http://www.langfordvets.co.uk/
The RCVS Charitable Trust has made two 'Blue Sky' grants of £20,000 each for research into feline rotavirus and equine gut bacteria.
One award has been made to Allison German and Kenton Morgan at the University of Liverpool as a Richard Daubney Research Fellowship. This will enable research to be undertaken into the molecular epidemiology and zoonotic potential of feline rotavirus in UK cats.
Allison said: "Feline rotaviruses have been identified in diarrhoeic children in Japan, Italy, Israel and America, but because of limited funding options, there has been no systematic study of rotaviruses in cats, so the prevalence, risk factors and zoonotic potential are unknown. I am pleased that the Trust has recognised the importance of emerging infectious diseases in companion animals and their potential role in animal and human health."
By assessing faecal samples from cats within Cats Protection Adoption Centres in the UK, the study aims to discover the prevalence of rotavirus in this cat population and broadly identify the strains of feline rotavirus that are circulating, including looking for any with identity to human strains. The study will also determine whether the molecular epidemiology of rotavirus in the cat population enables understanding of the diversification and evolution of rotaviruses in people.
A second Blue Sky award of £20,000 has been made to Chris Proudman and Alistair Darby, also at the University of Liverpool, to research the role of gut bacteria in horse health and disease. Called Metagenomic Analytical Utilities for Equines (MANURE), the project will sequence DNA from microbes taken from horse intestines, and analyse the diversity, composition and abundance of the microbial populations. This is expected to improve veterinary understanding of the role of equine gut bacteria, and benefit horses and their owners. Tools being developed to characterise and investigate equine gut microbiota, and findings expected, such as the discovery of novel bacteria, should also be useful to other research.
RCVS Trust Director Cherry Bushell said: "As usual, the standard of applications was very good, although we do continue to receive a relatively high number of applications for projects that the assessors judge to be more 'surveys' than genuine blue sky research.
"In deciding which research to fund, a number of factors are taken into account, such as the quality and strength of the research team, the likelihood of success, and whether a genuine gap in knowledge has been identified. For example, the feline rotavirus research could have important findings in the longer term if it is found that there is genuine risk to human health, and also shows clear potential for further study. Similarly, the equine gut bacteria study is likely to increase considerably knowledge over the longer term and to attract funding from elsewhere for further research."
Kruuse has announced that it has become the exclusive UK and Ireland distributor for Pulse Veterinary Technologies LLC shockwave systems, including the Versatron, Versatron 4paws and Equitron.
Shockwave therapy, otherwise known as extracorporeal shock wave therapy (ESWT), uses a high-energy sound wave that rapidly increases pressure as it travels through tissue. It is a non-invasive modality used to stimulate healing particularly in ligament, tendon or boney structures.
Andrew Groom, Managing Director, Kruuse UK Ltd said: "This agreement widens the Kruuse equine and small animal capital equipment profile within the UK and Ireland; increasing the range of technologies available to the veterinary practitioner , whilst providing aftercare support of existing shockwave users".
Eric Goorno , Chief Executive Officer, Pulse Veterinary Technologies LLC said: "This exciting partnership will further enhance our presence within the veterinary industry and allow Kruuse UK to bring leading edge technology to its customers, building upon its strong relationships within veterinary practices".
A research project funded by The Horse Trust has found that various types of ocular tumours can be successfully treated with mitomycin C, a cytotoxic antibiotic isolated from a bacterium.
The research concludes that mitomycin C offers a safe and cost effective alternative to current treatment options such as surgery and radiation.
The research project was led by Fernando Malalana, while working as The Horse Trust's Clinical Scholar in Equine Internal Medicine at University of Liverpool. Fernando is now working as a Clinician Teacher in Equine Internal Medicine at the university.
Ocular tumours are more difficult to treat than tumours in other parts of the horse's body due to the risk of damaging the eye. In the study, Malalana investigated the use of mitomycin C in treating ocular squamous cell carcinoma, the most common ocular tumour in horses, and occular sarcoids, skin tumors that frequently affect the eyelids .
Mitomycin C is an antibiotic isolated from a bacterium, Streptomyces caespitosus. It is known to have cytotoxic effects and has been used to treat tumours in horses before, but only in combination with surgery.
Currently, the main method of treating ocular squamous cell carcinoma is by removing the tumour surgically or with radiation. Both treatments are costly and have a number of associated risks. There is also the risk of damage or scarring to the eye.
Fourteen horses with ocular squamous cell carcinoma, three of which were affected bilaterally, were included in the study. Mitomycin C was applied to the conjunctival sac of the affected eye; in some of the cases the treatment was combined with surgery. Malalana found that of the 8 eyes treated with mitomycin C alone, clinical resolution occurred in 6 cases. Of the 9 eyes treated with both surgery and mitomycin C, clinical resolution occurred in 7 cases.
Mitomycin C was also used to treat various types of sarcoids found in the eye. Currently, the most effective treatment for occular sarcoids is radioactive wire. However, radioactive wire treatment is not ideal as it is expensive, only offered in two locations in the UK, and has potential health risks to the vet applying the wire due to exposure to radioactivity.
Six horses and two donkeys with occular sarcoids, including one horse that was affected bilaterally, were treated with mitomycin C, which was injected directly into the tumour. Malalana found that of the nine nodular and fibroplastic occular sarcoids treated with the antibiotic, all were completely cleared. However, the vets did not have good results with verrucous sarcoids.
Malalana said: "The results of this research should offer hope to the owners of horses that have eye tumours. We have already been contacted by vets from across Europe to find out more information about this treatment and hope that it will be offered to more horses with occular tumours in the future".
Vets at the University of Liverpool are now testing the use of mitomycin C on other tumours that are difficult to treat surgically, including melanomas near the horse's anus. So far, two cases have been treated, but it is too early to tell whether treatment has been successful.
Malalana's research has been submitted to Veterinary Ophthalmology journal.
Dunlops has changed its name to Henry Schein Animal Health.
David Hinton, Managing Director said: "As we change our name to Henry Schein Animal Health, we also reaffirm our company's strong commitment to offer a comprehensive array of products and services to help animal health practitioners in the United Kingdom operate more efficient and successful practices, and provide the best quality patient care.
"We have a new name, but we have the same strong team, the same values, and the same dedication to providing excellent service to our customers."
Henry Schein Animal Health’s expanded offerings include VetLink and Thrive. VetLink is a new e-commerce web site system that enables veterinary surgeons to access the growing internet sector, allowing you to sell anything from pet prescriptions to accessories online, to be delivered to your customers’ homes by Henry Schein Animal Health. Thrive is a new veterinary business analysis service that integrates with practice management software to use a Key Performance Indicator based approach that provides insight into a your practice and identifies areas where you can enhance your business.
The British Veterinary Association has welcomed the European Commission's Action Plan on Antimicrobial resistance (AMR), launched yesterday on the eve of European Antibiotic Awareness Day.
The Action Plan sets out 12 actions:
However, the association has expressed concern that the Commission has given only qualified support for new antimicrobials for veterinary use. Carl Padgett, President of the BVA, said: "There is much to be applauded in this action plan. In particular the BVA supports the calls for more and better coordinated research, more responsible use of antimicrobials in human and veterinary medicine, and the development of diagnostic tools to quickly and accurately identify the right drug for the right bug.
"The use of antimicrobials in the treatment and control of animal diseases is essential and the BVA supports the strong messages in this plan. Any option for managing AMR must be firmly rooted in sound scientific assessment of the risk.
"While the report recognises the difficulties that have led to the hampering of research into new antimicrobials for veterinary use, we are concerned that there is only qualified support from the Commission for the development of these new medicines for animal use.
"Research into new antimicrobials should be supported in both human and veterinary medicine. We need to ensure the creation of a more predictable regulatory environment to encourage new products for animals to be brought to the market.
"Finally, while the BVA supports the need for a new regulatory framework any new regulations must not impede the ability of veterinary surgeons to prescribe and dispense medicines according to their clinical judgement."
Meanwhile, Jill Moss of the Bella Moss Foundation added her voice to those calling for responsible use of antibiotics, highlighting recent research from the Royal Veterinary College that has established a clear link between pets with MRSA infection and human hospital-associated MRSA. What is less widely recognised, she says, is that resistant bacteria can be passed from human to animal.
The charity is now calling on health and veterinary professionals to work together to achieve a reduction in resistant infections by raising awareness and promoting the responsible use of antibiotics.
A research project funded by equine charity The Horse Trust has found that 40% of horses suffered a traumatic injury within the past year.
Only 13% of injuries occurred during ridden exercise, while 62% occurred while the horse was turned out in the field.
The research, which has been accepted for publication by the Equine Veterinary Journal, was carried out by Rosie Owen, who is currently working as The Horse Trust's Clinical Scholar in Equine Orthopaedics at the University of Liverpool.
Rosie said: "This Horse Trust-funded research shows that horses get injured relatively frequently - much more often than you would expect. Interestingly, most of the injuries happen during turnout, rather than during ridden exercise."
The results were obtained through analysing the responses from 652 randomly selected horse owners from north-west England, Midlands and North Wales, all of whom had a horse aged 15 years or younger. Owners sought veterinary treatment for 47% of the injuries reported, while the remainder were treated by the owner or a friend, or required no treatment.
Rosie identified a number of factors that were associated with an increased risk of injury. For example, horses that had been owned for a shorter period of time were found to be significantly more at risk of injury. She says the increased risk may be due to aggression from other horses when a new horse is introduced to a field, but owners can take various steps to reduce the likelihood of injury: "It's worth trying to avoid regular changes in group composition. A new horse should be introduced to the group gradually, preferably by providing adjacent stabling initially. Protective boots may help as the lower limbs are most at risk of injury. Also, if possible, the other horses in the field should have their shoes taken off during the period of adjustment, so they are less able to injure the new horse."
Rosie also found that horses turned out within larger groups were at an increased risk of injury. This is probably due to there being a larger hierarchy with multiple horses competing for dominance. However, she found that the risk of injury reduced when additional feeding areas were provided in the field: "If you provide hay or haylage to horses in the field, it's worth including an additional feeding area to reduce competition for food."
Other interesting findings included the lower incidence of injury in cob and pony breeds, compared to other breeds. Horses used competitively also had a higher risk of injury, which may be due to the additional athletic demands placed on these horses, or due to the way these horses are managed. Horses trained using Parelli methods were also found to be at an increased risk of injury, but as the numbers in this group were small, more research is needed to confirm this.
Although most of the injuries recorded in the survey occurred during turnout, 11% occurred in the stable, with most of the injuries affecting the head or eye. Rosie says owners can easily reduce the risk of stable injury: "There are various simple steps that owners can take to reduce the risk of injury in the stable. Try to provide hay from the floor, instead of in a hay rack, and make sure there are no protruding nails, hooks or sharp edges in the stable."
Rosie said that it would be useful to conduct further research to understand how injuries occur during turnout: "A lot of injuries are reported during turnout, but we're uncertain about what happened. It would be useful to observe the behaviour of horses in the field to see whether it's competition for food, or another factor, that is responsible for the high rate of injuries among horses."
Jeanette Allen, Chief Executive of The Horse Trust, said: "We are pleased that the research we've funded has provided such useful statistics on the risks of injury for horses. We hope that horse owners will follow some of the tips that Rosie has suggested to reduce the risk of their horse being injured."